Last updated: July 19, 2026
Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc., docket 1:21-cv-01118, is a U.S. patent infringement action tied to Zydus’ effort to launch a competing product covered by Neurocrine’s Orange Book-listed patent estate. The case posture, scope of asserted patents, and the resulting launch/entry risk turn on (i) which Neurocrine patents were asserted, (ii) whether Zydus filed a Paragraph IV certification, and (iii) the court’s schedule and any settlement terms that stayed or permitted entry.
Litigation status and outcome depend on the specific asserted patents and procedural events in docket 1:21-cv-01118. Without the docket’s claim lists, asserted patent numbers, and order/settlement entries, a complete, accurate, and litigation-grade analysis cannot be produced.
1:21-cv-01118 Neurocrine v. Zydus: What is the lawsuit about and what patents are at issue?
What users need to know (featured snippet): Identify the asserted Orange Book patents (and their expiration dates), the accused Zydus product (strength and dosage form), and whether the case turns on a Paragraph IV ANDA/Hatch-Waxman dispute or a separate non-ANDA claim structure.
Which Orange Book-listed patents are typically asserted in Neurocrine vs. ANDA cases?
A Neurocrine-led infringement case in the U.S. almost always targets one or more of:
- Composition-of-matter patents covering active ingredient or crystalline/polymorph forms
- Formulation patents covering excipients, ratios, coating systems, or extended-release matrices
- Method-of-use patents tied to therapeutic regimens
- Manufacturing patents tied to particle engineering, granulation, milling, or sterilization
- Device/delivery patents when the drug uses a specialized delivery mechanism
Key litigation artifacts to extract from the docket
For a litigation summary that is actually actionable, you must pull from the docket and pleadings:
- Complaint and infringement allegations (asserted claims/patents)
- Zydus’ responsive filings and any non-infringement/invalidity theories
- Claim construction proceedings (Markman) and court claim construction orders
- Any PI/TRO/temporary restraining order filings (if present)
- Final judgment, dismissal, or settlement-and-dismissal document
When was Neurocrine v. Zydus 1:21-cv-01118 filed and what are the procedural milestones that matter?
Featured snippet answer: The milestones that control launch timing are:
- Complaint filing date
- Service date
- Answer and infringement/invalidity contentions schedule
- Markman hearing and claim construction order
- Dispositive motions (summary judgment) schedule
- Trial date and final judgment (or settlement/dismissal)
Hatch-Waxman timing that drives entry risk
If the case is tied to an ANDA with Paragraph IV:
- Filing triggers a 30-month stay (if all statutory prerequisites are met)
- Settlement can convert the dispute into a carve-out/entry authorization with a negotiated launch date
- Court decisions on patent validity/infringement determine whether the stay ends early or expires naturally
Settlement vs. judgment outcomes
For business planning, settlement terms are decisive:
- Does the settlement specify a launch date?
- Are there carve-outs by strength, dosage form, or formulation?
- Is there a defined period of exclusivity or partial stay?
- Are there “delayed launch” commitments paired with non-appeal obligations?
Which claims and infringement theories did Neurocrine assert against Zydus (composition, formulation, or method-of-use)?
Featured snippet answer: In a patent infringement case, the asserted claims determine:
- Whether the dispute is about active ingredient identity (usually composition patents)
- Release technology or excipient systems (usually formulation patents)
- A prescribed treatment regimen (usually method-of-use patents)
- A manufacturing process (often harder to design around)
Claim-type map for an ANDA competitor
A typical claim map in Neurocrine-led ANDA litigation looks like:
- One or more claims targeting drug substance form or crystal properties
- One or more claims targeting extended-release matrix or coating
- One or more claims targeting use in a defined indication or dosing schedule
How Zydus usually contests (invalidity and non-infringement)
Typical defenses include:
- Non-infringement: Zydus product does not meet claim limitations (form, particle size, dissolution profile, excipient structure)
- Invalidity: anticipation/obviousness under §§102/103, or lack of enablement/definiteness
- Statutory defenses: if asserted claims are invalidated or not enforceable
What does the court docket show about claim construction, summary judgment, and trial or dismissal in 1:21-cv-01118?
Featured snippet answer: For litigation-grade analysis, the court record must be read for:
- Claim construction outcomes (which terms narrowed or broadened)
- Whether summary judgment disposed of any patents or claims
- Whether the case ended in a final judgment or settled/dismissed
Why claim construction is the driver
In a patent case, claim construction often determines:
- Infringement likelihood for each asserted claim
- Whether invalidity theories still fit the construed claim scope
- Whether parties settle after Markman
What to look for in orders
Orders that change risk materially:
- “Construction of disputed terms” orders
- “Order on summary judgment” or “motion to dismiss”
- “Stipulation of dismissal” or settlement termination order
How does this Neurocrine v. Zydus case affect generic or biosimilar entry risk and launch timing?
Featured snippet answer: Entry risk is driven by:
- The number of asserted patents that survive early procedural stages
- Whether the court enters injunction or whether the parties settle
- The length of any 30-month stay and whether it is extended/terminated
Paragraph IV and 30-month stay mechanics
If Zydus filed a Paragraph IV ANDA:
- FDA cannot approve final approval until the stay expires or the litigation is resolved
- A settlement can allow earlier launch at an agreed date while keeping at least one patent protected via delay or injunction terms
Design-around and “launch while litigation is pending”
Companies sometimes manage risk by:
- Seeking an agreed “launch-at-risk” window after certain patents are found invalid or not infringed
- Entering only with a formulation or strength not covered by a narrowed claim
What is the Orange Book status of the patents implicated in 1:21-cv-01118?
Featured snippet answer: Orange Book status includes:
- Listing numbers
- Patent expiration dates
- Exclusivity types (180-day exclusivity, 5-year exclusivity, orphan exclusivity, etc.)
- Whether the patents are “active” listings for the relevant NDA/strength
How Orange Book entries connect to infringement allegations
To connect docket allegations to Orange Book:
- Match asserted patent numbers from the complaint to Orange Book listing numbers
- Map each patent to the affected dosage form and strength
- Use the expiration dates to estimate the “non-litigation” end date for exclusivity
Which companies are likely impacted by this litigation beyond Neurocrine and Zydus?
Featured snippet answer: Impact typically extends to:
- Other ANDA filers targeting the same reference product
- Market entrants waiting on regulatory approval and litigation outcomes
- Investors monitoring whether a block of patents is likely to withstand challenges
Co-pending challenges
If other ANDA filers filed:
- Parallel Paragraph IV cases may share similar patent estates or technology
- Settlements can create market entry staggerings that change competitive dynamics
Patent strength analysis: How strong is Neurocrine’s estate likely to be in 1:21-cv-01118?
Featured snippet answer: Strength is assessed by:
- Likelihood of valid claims surviving obviousness/anticipation
- Whether accused product design around is plausible given claim scope
- Whether court decisions (Markman and summary judgment) already narrowed exposure
Litigation signals that indicate strength
- Early court findings that construe key limitations in the patentee’s favor
- Denial of dispositive motions by the generic challenger
- Settlement after claim construction usually indicates risk compression for the challenger
What formulation and manufacturing/IP barriers exist for Zydus or other challengers?
Featured snippet answer: Barriers usually fall into:
- Substantive formulation limitations (ratio, particle morphology, dissolution profile)
- Manufacturing controls needed to achieve defined in-process specs tied to claims
- Analytical method constraints that determine whether product meets claim-defined properties
Where design-around usually fails
Design-around attempts often fail when:
- Claims cover broad ranges that still include the challenger’s formulation
- Process claims are hard to separate from standard manufacturing steps
- Claim scope is defined by functional outcomes (e.g., dissolution curves) that are difficult to alter without performance loss
Key takeaways
- Docket 1:21-cv-01118 is a Neurocrine v. Zydus U.S. patent dispute whose business significance is tied to Orange Book-listed patents and Paragraph IV entry timing mechanics.
- A litigation-grade summary requires docket-specific details: asserted patent numbers, claims at issue, procedural history, and any settlement/judgment text. Those data are not present in the prompt, so a complete, accurate infringement and timing analysis cannot be completed here.
- The practical entry-risk outcome depends on which patents survived and whether the case ended via judgment or settlement with a defined launch date.
FAQs
1) Does docket 1:21-cv-01118 involve Paragraph IV ANDA litigation?
Answer requires the ANDA/Plaintiff alignment and certification record, which is not provided.
2) What is the earliest potential launch date after a 30-month stay in Neurocrine v. Zydus cases?
Answer depends on the stay-trigger event date and whether a settlement or court order ended the stay early.
3) Do settlements in Neurocrine patent cases typically include strength carve-outs?
Answer depends on settlement terms entered in the docket.
4) Which types of patents (formulation vs. method-of-use) most often drive outcomes in Neurocrine-driven generic disputes?
Answer depends on the asserted claims list in this specific case.
5) How do Markman claim constructions usually change infringement risk for Zydus-style design-arounds?
Answer depends on the exact claim construction orders issued in 1:21-cv-01118.
References
No sources were provided or cited in the prompt for docket 1:21-cv-01118.
